RBC Capital analyst Conor McNamara raised the firm’s price target on Danaher to $282 from $254 and keeps an Outperform rating on the shares after its Q4 earnings beat. The firm maintains that 2024 will be a year of outperformance in the Life Science Tools sector. As the biopharma market embarks on the next generation of therapeutics, including biosimilars, mRNA vaccines / therapies, and cell & gene therapy, Danaher is aligning itself to offer end-to-end solutions for customers, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DHR:
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher (NYSE:DHR) Drops on Dismal Q4 Numbers
- Danaher sees FY24 revenue down low-single digits, consensus $24.05B
- Danaher sees Q1 revenue down high-single digits, consensus $5.73B
- Danaher Reports Fourth Quarter and Full Year 2023 Results
